ICYMI: New Drugs Push Pharmaceutical Profits Up

According to an article via SFgate.com, “Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer Inc., Merck & Co. and Bristol-Myers...

Teva Ready to Divest Operations to Win Regulatory Nod for Mylan Buy

In a press release via PharmaVoice.com, “Generic drugmaker Teva Pharmaceutical Industries Ltd said it could “promptly” divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV…Teva plans to work...

Sanofi Agrees to R&D Partnership with Evotec

In an announcement via Genetic Engineering & Biotechnology News, “Evotec said yesterday it hammered out a definitive agreement for a five-year, minimum-guaranteed €250 million (nearly $270 million) strategic alliance with Sanofi focused on developing...

Valeant Pharmaceuticals Increases Offer for Salix

According to Reuters.com, “Valeant Pharmaceuticals has increased its takeover offer for Salix Pharmaceuticals to $10.96 billion in cash…bumping out Endo International Plc, the only other bidder for the maker of gastrointestinal drugs.”  Salix has...